![][1] A community of senior and early career oncologists were asked to participate in group consultations and individual interviews to reflect on the importance of Phase 1 trials, who makes them possible, the value of networks, and the challenges and opportunities presented by the COVID-19 pandemic. Over the following components, you will see quotes and summaries of what emerged from these sessions. Cancer experts were pooled from the UK Experimental Cancer Medicine Centres (ECMCs) network, Clinical Trials Units and University Cancer Institutes as well as internationally from Malawi. Participants ranged from early career clinical fellows to senior clinical academics and research scientists. Expertise ranged from phase one specialists, heads of clinical trials units, and childhood cancer specialists. The participants' discussions were written down during the sessions using a digital collaboration platform (Miro), and were then also transcribed using the recordings. For the analysis, we focused on important recurring themes, classifying within the structure used during the consultations. -The Importance of Phase 1 Trials -The Impact of COVID-19 on Phase 1 Trials -Who makes a Phase 1 Trial happen? -Networks and Stakeholders -Potential future consequences of Early detection and prevention -Changing Dynamics You can view the full enhanced report here: https://osf.io/azg8e/ You can download the full enhanced report here: https://osf.io/azg8e/download [1]: https://mfr.de-1.osf.io/export?url=https://osf.io/ns94a/?direct%26mode=render%26action=download%26public_file=False&initialWidth=759&childId=mfrIframe&parentTitle=OSF+%7C+Firstinhuman5.jpg&parentUrl=https://osf.io/ns94a/&format=2400x2400.jpeg